We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Approximates Human Performance in Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 25 Jul 2016
Artificial intelligence (AI) methods that train computers to interpret pathology images could make pathologic diagnoses more accurate.

Researchers at Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) and Harvard Medical School (HMS; Boston, MA, USA) have developed a machine-learning algorithm that can be used for a range of applications, including speech and image recognition. More...
The algorithm teaches machines to interpret complex patterns and structures observed in real-life data by building multi-layer artificial neural networks, in a process which is thought to show similarities with the learning process occurring in the neurons of the neocortex, the region where thinking occurs.

The researchers trained the computer to distinguish between cancerous tumor regions and normal regions, based on a deep multilayer convolutional network that began with hundreds of training slides for which a pathologist has labeled regions of cancer and regions of normal cells. They then extracted millions of small training examples and used deep learning to build a computational model to classify them. The researchers then identified the specific training examples for which the computer was prone to making mistakes, and re-trained it using greater numbers of the more difficult training examples, gradually improving the computer’s performance.

The computers performance was tested in a competition at the 2016 International Symposium of Biomedical Imaging (ISBI), held during April in Prague (Czech Republic). The competition involved examining images of lymph nodes to decide whether or not they contained breast cancer. The computer algorithm identified correctly 92% percent of the time, nearly matching the 96% success rate of a human pathologist. The algorithm placed first in two separate categories, competing against private companies and academic research institutions from around the world. A technical report describing the approach was posted on June 18, 2016, on the arXiv.org repository.

“Peering into the microscope to sift through millions of normal cells to identify just a few malignant cells can prove extremely laborious using conventional methods. We thought this was a task that the computer could be quite good at,” said pathologist Andrew Beck, MD, PhD, director of bioinformatics at the Cancer Research Institute at BIDMC. “But the truly exciting thing was when we combined the pathologist’s analysis with our automated computational diagnostic method, the result improved to 99.5% accuracy. Combining these two methods yielded a major reduction in errors.”

“When we started this challenge, we expected some interesting results. The fact that computers had almost comparable performance to humans is way beyond what I had anticipated,” said Jeroen van der Laak, PhD, of Radboud University Medical Center (The Netherlands), an organizer for the competition. “It is a clear indication that artificial intelligence is going to shape the way we deal with histopathological images in the years to come.”

Related Links:
Beth Israel Deaconess Medical Center
Harvard Medical School

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.